5BaBB, ArpinC, VidaillacC, et al. Activity of gatifloxacin in an in vitro pharmacokinetie- pharmacodynamic model agaist staphylococcus aureus strains either susceptible tociprofloxaein or exhibiting varlons lev- els and mechanism of jprofloxacin resistance [ J]. Antimicrob AgentsChemother,2006,50 ( 6 ) : 1931.
6Wang T, TanakaM, Sato K. Detction of grlA and gyrA mutations in 344 staphylococcus anreus strains [ J ] . Antimicrob Agents Chemother , 1998,42(2) :236 -240.
7Fournier B, Hooper D. Mutations in topoisomerase IV and DNA gy- rase of staphlococcus aureus : novel pleiotropic effects on quinolone and coumarin activity [ J ]. Antimcrob Agents Chemother, 1998,42 (1) :121 -128.
8Tanaka M, Onodera Y, Uchicla Y, et al. Quinolone resistance muta- tions in the GrlBprotein of staphylococcus aureus [ J]. Antimicreb A- gents Chemother, 1998,42( 11 ) :3044.
9Sehmitz FJ, Jones ME, Homfann B, et al. Charaetemitiong of grlA, grlB,gyrA and gyrB mutations in 116 unrelated isolates of staphylococcus aureus and effects of mutations on ciprofloxacin MIC [ J ] ~ Antimicrob Agents Chemother, 1998,42 (5) : 1249 - 1252.
10Kukeishi A, Diver JM, Beckthold B ,et al, Cloning and nucleotide seqience of P. aeruginosa gyrA gene from PA01 and quinolone - resistant clinical isolates [ J ]. Antimicrob Agents Chemother, 1994,38 ( 9 ) : 1994 - 1952.
2Diskalenko VV,Bryzgalova SV,Kurmashova LM,et al.Two cases of rare atypical localization of the petrosquamosal venous sinusis in the patients presenting with chronic suppurative epitympanitis complicated by cholesteatoma[J].Vestn Otorinolaringol,2011,:37-39.
